Drug Discovery

#Cell and gene therapy #Drug development #Drug discovery #Webinar

Learn about sustaining growth and maximising opportunities in CGT

Cell and gene therapies (CGT) are transforming the way diseases are treated. As research progresses it is hoped that cell and gene therapies will offer innovation for the future. Join this free webinar, hosted by DDW and supported by BPS Bioscience and Benchling, to learn… Read More

#News

#AI #Antimicrobial resistance (AMR) #Bioscience #Drug development #Europe #Phage therapy #Research

Grant will allow development of phage therapy diagnostic platform 

Vésale Bioscience, a company in the research and development of solutions and treatments using phage therapy for multi-resistant infections, has received €1.8 million in grants from the European Innovation Council (EIC) Accelerator Fund for its PhageDiag project.  The project is a phagogram using artificial intelligence (AI) that… Read More

#News

#Cell and gene therapy #Drug development #Drug discovery #Guide

Latest DDW Guide: Exclusive insight into cell & gene therapy

DDW has published the first of its new Guide Series, Where is the global innovation and the opportunity in cell and gene therapy? It is sponsored by Astrea BioSeparations and Benchling.  In this free, exclusive guide, you will learn more about:  The successes… Read More

#News

SLAS Image Cover
#AI / data analytics / healthtech / informatics #Drug discovery #Lab automation #SLAS2023

Exclusive DDW SLAS2023 supplement out now  

The DDW SLAS2023 supplement is out now.  Ahead of SLAS2023 which takes place 25 February – 1 March, the supplement explores the innovations and technologies that are driving drug discovery and laboratory research.  The DDW SLAS2023 supplement looks towards the event and covers key topics including:  … Read More

#News

#Cancer research #Clinical trials #Drug development #Drug discovery #Phase I trial #Phase II trial #Phase III trial

DDW Highlights podcast: 23 January 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Clinical trials have led our news section this week, with positive results… Read More

#News

#Clinical trials #Drug development #EU #FDA #Regulatory

Regulatory affairs in 2023: Key trends and changes  

Dr Julie Warner is Vice President of Regulatory Affairs at global drug development consultancy, Boyds. In this article, she provides her expert insights into the key regulatory developments likely to shape the global drug development industry this year.    Implementation of the EU Clinical Trials… Read More

#Business & Investment #Exclusive Content #Opinion #Regulatory #Trends & Analysis

#Biopharma #Cell and gene therapy #Drug discovery #Stem cells

The use of base editing in stem cell-based therapies

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies.   Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding… Read More

#Exclusive Content

Microplate
#Assay development optimisation & technology #Aurora Microplates #Drug discovery #Microplate readers

High performance microplates for discovery sciences

This paid-for advertorial by Aurora Microplates appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 Aurora Microplates is focused on making the highest quality, highest performing microplates available. The company uses the best materials, the cleanest and most precise moulding operations and facilities to deliver high performance microplates in… Read More

#Exclusive Content

#Cancer research #Clinical trials #Drug development #Drug discovery #Phase I trial #Phase II trial #Phase III trial

This week in drug discovery (16-20 January)

News round-up for 19-20 January by DDW Digital Content Editor Diana Spencer. Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good news from Alto Neuroscience, everImmune, Avacta and Abionyx, though unfortunately things are not… Read More

#News

#Cancer research #Drug development #Drug discovery #Guide #Oncology #Precision medicine

Trends in precision medicine: Cancer

This is an extraordinarily exciting time to be involved in precision medicine for cancer. This new whitepaper reviews some of the topics and trends in this emerging research area, including: 3D cultures: Spheroids and organoids Organoids in cancer research Tumour microenvironments Organ-on-a-chip and body-on-a-chip 3D bioprinting… Read More

#Resources

Protesting against health inequalities
#ABPI #Collaboration #Drug discovery #Drug innovation #NHS #Pharma #UK

NHS/industry collaboration could improve access to drugs

Collaborative working between the NHS and industry could reduce variations in uptake of innovative treatments across the UK, a joint report from NHS Confederation and ABPI argues.   Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and… Read More

#News

#Clinical trials #Drug discovery

Exclusive expert insights into clinical trials

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with two experts… Read More

#News

#Appointment #Drug discovery #New appointment

Five key drug discovery appointments

1. Antonin (Tony) de Fougerolles, Etherna  Antonin (Tony) de Fougerolles has joined the Etherna board of directors as an independent member.  He is currently the CEO of Evox Therapeutics. As founding Chief Scientific Officer (CSO) at Moderna Therapeutics, he pioneered modified mRNA.  2. Dr Xavier Jacq, Ubiquigent… Read More

#News

#Collaboration #Drug development #Drug discovery #Mergers and acquisitions #Partnership

Catch up with the latest DDW Highlights episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Once again, research partnerships and licence agreements have dominated the news… Read More

#News

#Collaboration #Drug development #Drug discovery #Mergers and acquisitions #Partnership

This week in drug discovery (9-13 January)

News round-up for 9-13 January by DDW Digital Content Editor Diana Spencer. Once again, research partnerships and licence agreements have dominated the news this week, as drug discovery companies seek new ways to combine their expertise to address unmet medical needs.  The top stories: … Read More

#News

Remyelination
#Acquisition #CNS #Drug discovery #Pheno Therapeutics #Phenomics #Phenotyping

Pheno Therapeutics buys rights to potential remyelination drug

Pheno Therapeutics has entered an agreement with UCB for the rights to develop, manufacture and commercialise a preclinical-stage programme of novel small molecules designed to promote remyelination.   “Pheno Therapeutics utilised its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology… Read More

#Business & Investment #News